This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: December 13, 2006
Last updated: March 27, 2013
Last verified: March 2013

This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease.

Patients also had a 2 year follow-up to assess disease progression where no drug was administered.

Condition Intervention Phase
Alzheimer's Disease Biological: CAD106 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Time-lagged, Parallel Group Study in Patients With Mild to Moderate Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and Aß-specific Antibody Response Following Three Subcutaneous Injections of CAD106

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Tolerability/safety assessments (physical/neurol.exam., ECG, vital signs, standard and special immunological laboratory evaluations, MRIs, EEGs, AE/SAE monitoring). [ Time Frame: at multiple timepoints including but not limited to screening, baseline, and through the end of the study to Week 52. ]
  • Antibody titers (IgM and IgM titers against amyloid and carrier protein). [ Time Frame: at multiple timepoints including but not limited to baseline and through the end of the study to Week 52 ]

Secondary Outcome Measures:
  • Immune response, cognitive and functional assessments [ Time Frame: at multiple timepoints including but not limited to baseline and through the end of the study to Week 52 ]

Enrollment: 58
Study Start Date: June 2005
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Biological: CAD106
Placebo Comparator: 2
Drug: Placebo


Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • males and/or females patients between 50 to 80 years of age (both inclusive).
  • female patients must be without childbearing potential (post-menopausal or surgically sterilized).
  • diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria (Diagnostic and Statistical Manual of Mental Disorders, 4th edition).
  • mild to moderate AD as confirmed by Mini-Mental State Exam score of 16 to 26 (both inclusive) at screening.
  • able to provide written informed consent and having a responsible caregiver that can provide written assent prior to study participation. For patients who have been declared mentally incompetent, a legal representative will need to provide informed consent on their behalf.

Exclusion Criteria:

  • previously participated in an AD vaccine study and received active treatment
  • history or presence of an active autoimmune and/or cerebrovascular disease
  • history or presence of seizures, with an acute or chronic inflammation
  • clinically relevant atopic condition, who suffer from an other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression)
  • immunosuppressive treatment including systemic steroids
  • obtained a vaccination (e.g. against influenza) within 4 weeks before the first study drug injection
  • advanced, severe, progressive or unstable disease that might interfere with the safety of the patient
  • started treatment with psychotropic medication within 3 months (4 weeks for SSRIs and other newer antidepressants without anticholinergic properties) prior to randomization with the exception of mild hypnotic drugs (e.g. zolpidem, zopiclone, oxazepam) and low doses of neuroleptic drugs (e.g. up to 2 mg risperidone).

Patients, who are on stable treatment with cholinesterase-inhibitors (ChEIs) and/or memantine for at least 3 months, and/or with SSRIs and/or other newer antidepressants (without anticholinergic properties) for at least 4 weeks before randomization, can be included into the study.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00411580

Novartis Investigative Site
Malmo, Sweden, 204 02
Novartis Investigative Site
Stockholm, Sweden, 141 86
Novartis Investigative Site
Stockholm, Sweden
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Principal Investigator: Novartis Investigator site
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00411580     History of Changes
Other Study ID Numbers: CCAD106A2101
Study First Received: December 13, 2006
Last Updated: March 27, 2013

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Mild, moderate Alzheimer's Disease (AD), Aß-specific antibody, CAD106

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders processed this record on September 21, 2017